M&A Deal Summary

Zymeworks Acquires Kairos Therapeutics

On March 22, 2016, Zymeworks acquired life science company Kairos Therapeutics

Acquisition Highlights
  • This is Zymeworks’ 1st transaction in the Life Science sector.
  • This is Zymeworks’ 1st transaction in Canada.
  • This is Zymeworks’ 1st transaction in British Columbia.

M&A Deal Summary
Date 2016-03-22
Target Kairos Therapeutics
Sector Life Science
Buyer(s) Zymeworks
Deal Type Add-on Acquisition

Target

Kairos Therapeutics

Vancouver, British Columbia, Canada
Kairos Therapeutics, Inc. is a bio pharmaceutical company specialists in the discovery and development of antibody drug conjugates (ADCs), spun out of The Centre for Drug Research and Development (CDRD).

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Zymeworks

Vancouver, British Columbia, Canada
Category Company
Founded 2003
Sector Life Science
DESCRIPTION

Zymeworks, Inc. is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal